NCT06970496View on ClinicalTrials.gov

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
Interventions
DRUG

B019

B019： Intravenous infusion, 2.0×10\^6 cell/kg-8.0×10\^6 cell/kg

Trial Locations (7)

Unknown

Sun Yat-sen University Cancer Center, Guangzhou

Zhujiang Hospital of Southern Medical University, Guangzhou

Jiangxi Cancer Hospital, Nanchang

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Shanghai General Hospital, Shanghai

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

Xijing Hospital, Xi'an

All Listed Sponsors
lead

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

INDUSTRY